Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2010 Nov 30.
Published in final edited form as: Mol Cancer Ther. 2010 Sep;9:2637. doi: 10.1158/1535-7163.MCT-10-0671

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

PMCID: PMC2993116  NIHMSID: NIHMS231534

Correction: ErbB-Inhibitory Protein: A Modified Ectodomain of Epidermal Growth Factor Receptor Synergizes with Dasatinib to Inhibit Growth of Breast Cancer Cells

In this article ( Mol Cancer Ther 2010;9:1503–14), which was published in the June 1, 2010 issue of Molecular Cancer Therapeutics (1), the labels of Figs. 1B and C were not aligned correctly. The correct Figure 1 appears here. The online article has been changed to reflect this correction and no longer matches the print.

Figure 1.

Figure 1

Open in a new tab

References

  • 1.Nautiyal J, Yu Y, Aboukameel A, et al. ErbB-inhibitory protein: A modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. Mol Cancer Ther. 2010;9:1503–14. doi: 10.1158/1535-7163.MCT-10-0019. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES